News | April 27, 2026
Sun Pharma to acquire Organon in $11.75 billion all-cash deal
Acquisition to expand the company's women’s health and biosimilars footprint, positioning it among top 25 drugmakers globally
Acquisition to expand the company's women’s health and biosimilars footprint, positioning it among top 25 drugmakers globally
This includes 14.3 million views on YouTube and 9.8 million views on Meta platforms to amplify preventive heart health message
Company to launch product after the expiry of semaglutide patent in India
UNLOXCYT is an evolution in checkpoint inhibition and is now available for the treatment of adults in the U.S. with mCSCC or laCSCC who are not candidates for curative surgery or curative radiation
Sun Pharma to set up Rs. 3,000 crore greenfield formulations facility in MP
Both companies will promote, market and distribute Sodium Zirconium Cyclosilicate in India under different brand names
Sun Pharmaceutical Industries has reported total income of Rs. 14,948.23 crore during the period ended September 30, 2025
Sun Pharma's Halol plant gets OAI classification from US FDA inspection
India Formulation sales accounted for 34.2% of total consolidated sales for the quarter
The INSPIRE-1 and INSPIRE-2 trials are Phase 3 studies assessing the efficacy and safety of tildrakizumab 100 mg (ILUMYA) in adults with active psoriatic arthritis (PsA)
Subscribe To Our Newsletter & Stay Updated
